[Treatment of patients with dermatomycoses with a new drug form of griseofulvin, griseofulvin-forte suspension].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001799:Blood Sedimentation; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003881:Dermatomycoses / Q000188:drug therapy*; D004802:Eosinophilia / Q000139:chemically induced; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006118:Griseofulvin / Q000008:administration & dosage* / Q000009:adverse effects; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007964:Leukocytosis / Q000139:chemically induced; D009181:Mycoses / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D013535:Suspensions; D014005:Tinea / Q000188:drug therapy; D014007:Tinea Favosa / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D013535:Suspensions; D006118:Griseofulvin
Lechenie bol'nykh dermatomikozami novoĭ lekarstvennoĭ formoĭ grizeoful'vina-suspenzieĭ grizeoful'vina-forte.